Abstract
Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Current Nanoscience
Title:Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Volume: 9 Issue: 1
Author(s): Sumeet Sood, Natarajan Jawahar, Kunal Jain, Kuppusamy Gowthamarajan and Subramania Nainar Meyyanathan
Affiliation:
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Abstract: Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Export Options
About this article
Cite this article as:
Sood Sumeet, Jawahar Natarajan, Jain Kunal, Gowthamarajan Kuppusamy and Nainar Meyyanathan Subramania, Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability, Current Nanoscience 2013; 9 (1) . https://dx.doi.org/10.2174/1573413711309010007
DOI https://dx.doi.org/10.2174/1573413711309010007 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |
Call for Papers in Thematic Issues
Role of nanomaterials in fabrication of coatings, Machining and Joining
The application of nanoscience has brought about a revolution in the field of mechanical engineering by providing novel materials, boosting manufacturing processes, and generating cutting-edge products. The purpose of this special issue is to investigate the enormous impact that nanoscience has had on mechanical engineering, with a particular emphasis on ...read more
Advanced Inorganic Nanocomposites and Their Emerging Applications
This special issue collection will highlight developments on the recent trends about the synthesis of metal oxides, nanoclusters, biomaterials, 2D nanomaterials, nanocrystals, nanocomposites, etc. and their applications in electrochemical systems, tissue regeneration, energy storage and harvesting, sensors, etc. The novelty of the methods in the chemical synthesis and their characterizations, ...read more
Applicability of Nanotechnology for Performance Enhancement of Clean Energy Technologies
Population growth, industrialization, and improvement in living quality would lead to further increase in energy demand in near future. Regarding the disadvantages of fossil fuels such as fluctuations in their price, high emissions of greenhouse gases and restriction of their sources, it is crucial to use and exploit alternative energy ...read more
Graphene and 2D Materials for Energy Storage and Conversion
This thematic issue will discuss the recent advances in graphene-based nanomaterials for different energy technologies. Graphene possesses a high surface area, and stable structure and exhibits many interesting electronic, optical, and mechanical properties due to its 2D crystal structure. Graphene is of both fundamental interest and suitable for a wide ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Peak Treadmill Exercise Echocardiography
Reviews on Recent Clinical Trials New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease
Current Bioactive Compounds The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design